Open Access Open Access  Restricted Access Subscription Access

An Essential Parameters of Fosinopril Include Objectives, Indications, Mechanism of Action, Administration, Adverse Effects, Contra - Indications, Toxicity and Health Care Team Out Comes

Srinivas G., Ramanjaneyulu D.V., Satyanarayana Murthy S., Muralinath E., Guruprasad M., Hari Kiran M., Shaik Mahabooob Basha, Kundara Giridhar Reddy, Kasireddy Guthami, Mopoori Kalyan, Sai Charan B., Sainath Reddy T., Ramesh U., Rahul P., Rajitha V.

Abstract


Angiotensin-converting enzyme (ACE) inhibitors, which have been used to treat cardiovascular diseases for almost thirty years, are related to fosinopril. Both heart failure and hypertension can now be treated with fosinopril, according to the US Food and Drug Administration (FDA). As a competitive inhibitor of ACE, fosinopril prevents angiotensin I from becoming an effective vasoconstrictor, angiotensin II. The following additional ACE inhibitors are authorized in the US: trandolapril, captopril, enalapril, lisinopril, benazepril, quinapril, ramipril, moexipril, and fosinopril.


Full Text:

PDF

References


National Institute of Diabetes and Digestive and Kidney Diseases. (2018, February 11). Angiotensin-converting enzyme inhibitors. In LiverTox: Clinical and research information on drug-induced liver injury [Internet]. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK547852/

Elliott, W. J. (2007). Systemic hypertension. Current Problems in Cardiology, 32(4), 201–259. https://doi.org/10.1016/j.cpcardiol.2007.01.001

Shettigar, U., Hare, T., Gelperin, K., Ilgenfritz, J. P., Deitchman, D., & Blumenthal, M. (1999). Effects of fosinopril on exercise tolerance, symptoms, and clinical outcomes in patients with decompensated heart failure. Congestive Heart Failure, 5(1), 27–34.

Erhardt, L., MacLean, A., Ilgenfritz, J., Gelperin, K., & Blumenthal, M. (1995). Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure: Fosinopril Efficacy/Safety Trial (FEST). European Heart Journal, 16(12), 1892–1899.

Borghi, C., Marino, P., Zardini, P., Magnani, B., Collatina, S., & Ambrosioni, E. (1998). Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: Results from the FAMIS study. American Heart Journal, 136(2), 213–225.

Huang, Y. H., Wang, H. T., Zhu, Q. Z., Zhang, H., Shen, W., & Wang, Y. (2003). [Combination therapy with losartan and fosinopril for early diabetic nephropathy]. Di Yi Jun Yi Da Xue Xue Bao, 23(9), 963–965.

Wei, A., Burns, G. C., Williams, B. A., Mohammed, N. B., Visintainer, P., & Sivak, S. L. (2003). Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney International, 64(4), 1462–1471. https://doi.org/10.1046/j.1523-1755.2003.00257.x

Yoshiyama, M., Nakamura, Y., Omura, T., Izumi, Y., Matsumoto, R., Oda, S., Takeuchi, K., Kim, S., Iwao, H., & Yoshikawa, J. (2005). Angiotensin converting enzyme inhibitor prevents left ventricular remodeling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart, 91(8), 1080–1085. https://doi.org/10.1136/hrt.2004.038810

Düsing, R. (2016). Pharmacological interventions into the renin–angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: Effects beyond blood pressure lowering. Therapeutic Advances in Cardiovascular Disease, 10(3), 151–161. https://doi.org/10.1177/1753944716633224

Song, J. C., & White, C. M. (2002). Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin-converting enzyme inhibitors: An update. Clinical Pharmacokinetics, 41(3), 207–224. https://doi.org/10.2165/00003088-200241030-00003

Ho, J. K., Moriarty, F., Manly, J. J., Larson, E. B., Evans, D. A., Rajan, K. B., Hudak, E. M., Hassan, L., Liu, E., Sato, N., Hasebe, N., Laurin, D., Carmichael, P. H., & Nation, D. A. (2021). Blood-brain barrier crossing renin-angiotensin drugs and cognition in the elderly: A meta-analysis. Hypertension, 78(3), 629–643. https://doi.org/10.1161/HYPERTENSIONAHA.121.17265

Zisaki, A., Miskovic, L., & Hatzimanikatis, V. (2015). Antihypertensive drugs metabolism: An update to pharmacokinetic profiles and computational approaches. Current Pharmaceutical Design, 21(6), 806–822. https://doi.org/10.2174/1381612820666141119145717

Greenbaum, R., Zucchelli, P., Caspi, A., Nouriel, H., Paz, R., Sclarovsky, S., O'Grady, P., Yee, K. F., Liao, W. C., & Mangold, B. (2000). Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. British Journal of Clinical Pharmacology, 49(1), 23–31. https://doi.org/10.1046/j.1365-2125.2000.00109.x

National Institute of Diabetes and Digestive and Kidney Diseases. (2018, February 6). Fosinopril. In LiverTox: Clinical and research information on drug-induced liver injury [Internet]. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK548055/

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., ... & Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012

Biggins, S. W., Angeli, P., Garcia-Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021). Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome: 2021 practice guidance by the AASLD. Hepatology, 74(2), 1014–1048. https://doi.org/10.1002/hep.31803

American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. (2019). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. Obstetrics & Gynecology, 133(1), e26–e50. https://doi.org/10.1097/AOG.0000000000003020

Buawangpong, N., Teekachunhatean, S., & Koonrungsesomboon, N. (2020). Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis. Pharmacology Research & Perspectives, 8(5), e00644. https://doi.org/10.1002/prp2.644

National Institute of Child Health and Human Development. (2024, November 15). Fosinopril. In Drugs and Lactation Database (LactMed®) [Internet]. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK501029/

Juárez-Cedillo, T., Martinez-Hernández, C., Hernández-Constantino, A., Garcia-Cruz, J. C., Avalos-Mejia, A. M., Sánchez-Hurtado, L. A., Islas Perez, V., & Hansten, P. D. (2016). Clinical weighting of drug–drug interactions in hospitalized elderly. Basic & Clinical Pharmacology & Toxicology, 118(4), 298–305. https://doi.org/10.1111/bcpt.12523

Flynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., ... & Urbina, E. M. (2017). Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics, 140(3), e20171904. https://doi.org/10.1542/peds.2017-1904

Oudit, G., Girgrah, N., & Allard, J. (2001). ACE inhibitor-induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis, and management. Canadian Journal of Gastroenterology, 15(12), 827–832. https://doi.org/10.1155/2001/248918

Ben Salem, C., Badreddine, A., Fathallah, N., Slim, R., & Hmouda, H. (2014). Drug-induced hyperkalemia. Drug Safety, 37(9), 677–692. https://doi.org/10.1007/s40264-014-0208-0

Schneir, A., & Masom, C. P. (2020). Lithium toxicity from the addition of an ACE inhibitor with an unexpected type I Brugada pattern ECG: Case files of the Medical Toxicology Fellowship at the University of California, San Diego. Journal of Medical Toxicology, 16(3), 321–328. https://doi.org/10.1007/s13181-020-00766-z

Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., ... & Schutte, A. E. (2020). 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension, 75(6), 1334–1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026

Duerr, M., Glander, P., Diekmann, F., Dragun, D., Neumayer, H. H., & Budde, K. (2010). Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clinical Journal of the American Society of Nephrology, 5(4), 703–708. https://doi.org/10.2215/CJN.08431109


Refbacks

  • There are currently no refbacks.